Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664404 · ClinicalTrials.gov registry record · Phase 3
Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 64
- Enrollment target
NCT00664404: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00664404 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00664404, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 64 participants
- Enrollment target
Study Summary
Objectives: * To evaluate neural correlates associated with emotional processing during nicotine withdrawal preferentially involving the amygdala and associated areas within the corticolimbic and mesolimbic circuitry. We hypothesize that relative to a pre-quit baseline, post-quit nicotine withdrawal will result in increased activity to negative emotional cues, in contrast to other cues, in one or more areas of interest, and particularly in the right cerebral hemisphere. * To determine if bupropion and varenicline moderate patterns of brain activation during post-quit nicotine withdrawal. We hypothesize that relative to placebo, bupropion and varenicline will attenuate the effects of post-quit nicotine withdrawal on emotional processing, reducing activation to negative emotional cues, relative to other cues, in one or more areas of interest, and particularly in the right cerebral hemisphere. * To determine if genotype (DRD2 TaqA2 allele and the ins variant of the -141C ins/del DRD2) moderates patterns of brain activation during post-quit nicotine withdrawal.
Interventions
- OTHER Functional Magnetic Resonance Imaging (fMRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00664404
The ClinicalTrials.gov registry entry for NCT00664404 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Functional Magnetic Resonance Imaging (fMRI) is the first listed.
NCT00664404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00664404 about?
NCT00664404 is a clinical study titled "Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal". Objectives: * To evaluate neural correlates associated with emotional processing during nicotine withdrawal preferentially involving the amygdala and associated areas within the corticolimbic and mesolimbic circuitry. We hypothesize that relative to a pre-quit baseline, post-quit nicotine withdrawa...
What is the current status of trial NCT00664404?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 2008-04.
What interventions are being tested in trial NCT00664404?
The interventions under investigation include: Functional Magnetic Resonance Imaging (fMRI) (OTHER).
Who is sponsoring clinical trial NCT00664404?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.